Specialty Pharmacy

Expert discusses whether epigenetic programs regulate human T cell exhaustion and whether epigenetic-based strategies can be used to enhance T cell-based therapies.

Bevacizumab-adcd (Vegzelma) is indicated for the treatment of nonsquamous non–small cell lung cancer; recurrent glioblastoma; metastatic colorectal cancer; persistent, recurrent, or metastatic cervical cancer; metastatic renal cell carcinoma; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Two Houston Methodist cancer researchers were granted a quarter of a million dollars each to study some of the most lethal cancers.

New research has shown significant promise for the use of CAR T-cell therapies in solid tumors.

KIN-2787 is a potential treatment for BRAF class II or III alteration-positive and/or NRAS mutation-positive, metastatic or unresectable, stage IIB to IV malignant melanoma.

Combination treatment with ibrutinib found to increase median progression-free survival by 2.3 years compared to the placebo.

There were approximately 250,000 new cases of prostate cancer identified in the United States in 2021, which is considered approximately 13% of all cancer cases.

The value of a patient-first approach and telehealth for addressing the complex health coordination needs of those with these pulmonary conditions has never been more critical.

Experts discuss insight from a recently published oncology drug shortages research project and HOPA’s plan to address related issues based on the project’s findings.

The annual report notes that progress in reducing cancer mortality is uneven among populations, with minority groups not seeing the same benefits from therapeutic advances.

Motivational Interviewing is a collaborative conversation style that can empower patients to stay the course and achieve better outcomes.

Specialty pharmacies need processes, systems and tools to quickly determine medication delivery status, reassure confidence, and alleviate patient anxiety.

Danielle Carnival, PhD, addressed the National Comprehensive Cancer Network Policy Summit on Friday.

The FDA accepted a supplemental New Drug Application for tucatinib to treat HER2 colorectal cancer, which could significantly improve outcomes for these patients.

The All of Us Research Program looks to enroll more than 1 million US individuals in the next 10 years to enable public access to medical data for research purposes.

Selpercatinib produced clinically meaningful and durable responses across a variety of tumor types in patients with RET-driven cancers.

Data showed that Black women, regardless of education level or income, are more likely to reside in disadvantaged neighborhoods, which may contribute to racial disparities in breast cancer.

Nivolumab is a biomarker that has been shown to benefit the survival of patients with stage 2 melanoma patients compared with placebo.

Pharmacists should get involved in all the various aspects of their business and with the different professional groups available.

Analytics allow for a better understanding of the needs of various patient populations and the barriers they face in accessing care.

Management of marginal zone lymphoma was impacted by the COVID-19 pandemic because some treatment options can reduce B-cell-produced antibodies.

NVG-111 is a humanized, tandem single-chain variable fragment ROR1 x CD3 BiTE being evaluated in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.

Eflapegrastism-xnst injection (Rolvedon, Spectrum Pharmaceuticals) is indicated to lower the incidence of infection, as demonstrated by febrile neutropenia, in adult patients with non-myeloid malignancies.

Researchers found differences in the variable importance of cancer mortality risk factors depending on an individual’s geographical region.

Prior authorizations have delayed time to treatment for patients and can directly impact clinical outcomes.

New research presented at ESMO Congress found that certain patients with advanced melanoma administered a combination of cemiplimab with fianlimab experienced a median progression-free survival of 2 years.

Researchers at the European Society for Medical Oncology Congress presented findings that show osimertinib may clinically reduce the risk of lung cancer recurrence.

Research suggests that rucaparib can increase progression-free survival by more than a year in women with advanced ovarian cancer.